Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

This study proposes that the addition of statins reduces the treatment delays or early discontinuations secondary to cardiotoxicity in patients with Stage I-III HER2 positive breast being treated with anti-HER2 therapy.

Trial Details

NCT ID

NCT05559164

Phase

PHASE2

Sponsor

Rutgers, The State University of New Jersey

Status

RECRUITING

Cancer Type

HER2 Positive Breast Cancer

Interventions

Lipitor 40mg Tablet

Locations (sample)

Elizabeth, New Jersey, United States|40.66399,-74.2107
Hamilton, New Jersey, United States|40.20706,-74.08125
Jersey City, New Jersey, United States|40.72816,-74.07764
Lakewood, New Jersey, United States|40.09789,-74.21764
Long Branch, New Jersey, United States|40.30428,-73.99236

Key Eligibility Criteria

Histologically and/or cytologically confirmed diagnosis of Stage I-III female breast cancer (including inflammatory breast cancer)
Scheduled to receive neoadjuvant/adjuvant HER2 targeted therapy
Between ≥18 years of age
Female patients of childbearing potential must have a negative pregnancy test (serum or urine) prior to enrollment. Female patients must agree to u…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →